RecruitingPhase 1NCT04886726

PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis

Studying Rare disorder potentially indicated for transplant or complication after transplantation

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Henry Ford Health System
Intervention: uhCG/EGF(drug)
Enrollment: 18 target
Eligibility: 18-70 years · All sexes
Timeline: 2021 – 2028

Study locations (1)

Henry Ford Hospital, Detroit, Michigan, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04886726 on ClinicalTrials.gov

Other trials for Rare disorder potentially indicated for transplant or complication after transplantation

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE2, PHASE3NCT03818334
Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
Hospital Israelita Albert Einstein

See all trials for Rare disorder potentially indicated for transplant or complication after transplantation →

← Back to all trials